blinatumomab
Selected indexed studies
- Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults. (N Engl J Med, 2024) [PMID:39047240]
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. (N Engl J Med, 2017) [PMID:28249141]
- Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children. (N Engl J Med, 2025) [PMID:39651791]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. (2023) pubmed
- Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults. (2024) pubmed
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. (2017) pubmed
- Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children. (2025) pubmed
- Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial. (2021) pubmed
- Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. (2018) pubmed
- Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. (2020) pubmed
- Blinatumomab: a historical perspective. (2012) pubmed
- Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. (2016) pubmed
- Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia. (2023) pubmed